Eukles Asset Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.41M Sell
9,471
-281
-3% -$65.5K 0.99% 35
2026
Q1
$2.38M Sell
9,752
-954
-9% -$222K 1.06% 34
2025
Q4
$2.22M Sell
10,706
-205
-2% -$40.5K 0.86% 41
2025
Q3
$2.02M Sell
10,911
-115
-1% -$19.7K 0.79% 42
2025
Q2
$1.68M Sell
11,026
-129
-1% -$19.8K 0.69% 47
2025
Q1
$1.85M Buy
11,155
+89
+0.8% +$13.9K 0.81% 44
2024
Q4
$1.6M Sell
11,066
-294
-3% -$45.6K 0.68% 50
2024
Q3
$1.84M Sell
11,360
-584
-5% -$93K 0.74% 47
2024
Q2
$1.75M Buy
11,944
+92
+0.8% +$13.7K 0.76% 45
2024
Q1
$1.87M Buy
11,852
+559
+5% +$89K 0.82% 42
2023
Q4
$1.77M Buy
11,293
+29
+0.3% +$4.45K 0.84% 42
2023
Q3
$1.75M Buy
11,264
+118
+1% +$19.5K 0.93% 38
2023
Q2
$1.84M Buy
11,146
+133
+1% +$21.5K 0.94% 38
2023
Q1
$1.71M Buy
11,013
+35
+0.3% +$5.65K 0.93% 42
2022
Q4
$1.94M Buy
10,978
+372
+4% +$64.2K 1.13% 34
2022
Q3
$1.73M Buy
10,606
+744
+8% +$126K 1.14% 35
2022
Q2
$1.75M Buy
9,862
+53
+0.5% +$9.44K 1.11% 34
2022
Q1
$1.74M Sell
9,809
-771
-7% -$131K 0.94% 39
2021
Q4
$1.81M Buy
10,580
+304
+3% +$49.8K 0.88% 45
2021
Q3
$1.66M Sell
10,276
-325
-3% -$55.4K 0.91% 42
2021
Q2
$1.75M Buy
10,601
+1,587
+18% +$263K 0.97% 40
2021
Q1
$1.48M Buy
9,014
+170
+2% +$27.5K 0.96% 41
2020
Q4
$1.39M Buy
8,844
+190
+2% +$28K 0.96% 42
2020
Q3
$1.29M Buy
8,654
+112
+1% +$16.6K 1% 39
2020
Q2
$1.2M Buy
8,542
+1,112
+15% +$162K 1.02% 42
2020
Q1
$974K Sell
7,430
-1,275
-15% -$181K 1.01% 42
2019
Q4
$1.27M Sell
8,705
-112
-1% -$15.2K 1.03% 41
2019
Q3
$1.14M Sell
8,817
-24
-0.3% -$3.16K 0.99% 45
2019
Q2
$1.23M Sell
8,841
-61
-0.7% -$8.44K 1.07% 42
2019
Q1
$1.24M Buy
8,902
+27
+0.3% +$3.62K 1.13% 41
2018
Q4
$1.15M Buy
+8,875
New +$1.24M 1.19% 38

Other funds holding JNJ

Eukles Asset Management's JNJ Position: Q2 2026 in Review

Eukles Asset Management reduced its Johnson & Johnson (JNJ) stake by 2.9% in Q2 2026, selling an estimated $65.5K and leaving 9,471 shares worth $2.41M. The position accounts for 0.99% of the portfolio, ranked #35.

Eukles Asset Management first reported a position in JNJ in Q4 2018 and has held it in 31 quarters since. 4,665 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Eukles Asset Management held 9,471 shares of Johnson & Johnson worth $2.41M as of Q2 2026.
  • Eukles Asset Management sold 281 Johnson & Johnson shares in Q2 2026, an estimated $65.5K.
  • Johnson & Johnson made up 0.99% of Eukles Asset Management's portfolio in Q2 2026, its #35 holding.
  • Eukles Asset Management first reported a position in Johnson & Johnson in Q4 2018 and has held it in 31 quarters since.
  • 4,665 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Eukles Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.